|Articles|January 15, 2003
- BioPharm International-01-01-2003
- Volume 16
- Issue 1
Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies
Author(s)Jill Wechsler
by Jill Wechsler Manufacturers are concerned about congressional efforts to establish a Medicare pharmacy benefit and to regulate research while FDA shifts regulation of biologics and other drugs.
Advertisement
Articles in this issue
over 22 years ago
Biotech World: Canada's Supreme Court says "No" to Harvard Mouseover 22 years ago
Guest Editorial: At the Governance Crossroadover 22 years ago
Reducing Costs by Facility Designover 22 years ago
Survival Strategies: Board Compensation Changing with the TimesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
